Astrid MurumÃ¤gi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6126707/publications.pdf

Version: 2024-02-01

21 papers	1,159 citations	858243 12 h-index	889612 19 g-index
21 all docs	21 docs citations	21 times ranked	2671 citing authors

#	Article	IF	Citations
1	Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia. Cancer Discovery, 2013, 3, 1416-1429.	7.7	334
2	Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. Scientific Reports, 2014, 4, 5193.	1.6	243
3	Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies. Clinical Cancer Research, 2018, 24, 794-806.	3.2	177
4	Drug response prediction by inferring pathway-response associations with kernelized Bayesian matrix factorization. Bioinformatics, 2016, 32, i455-i463.	1.8	87
5	Consistency in drug response profiling. Nature, 2016, 540, E5-E6.	13.7	76
6	Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting. Oncogene, 2019, 38, 3288-3300.	2.6	39
7	Glucocorticoids induce differentiation and chemoresistance in ovarian cancer by promoting ROR1-mediated stemness. Cell Death and Disease, 2020, 11, 790.	2.7	38
8	Drug-Sensitivity Screening and Genomic Characterization of 45 HPV-Negative Head and Neck Carcinoma Cell Lines for Novel Biomarkers of Drug Efficacy. Molecular Cancer Therapeutics, 2018, 17, 2060-2071.	1.9	33
9	Targeting ROR1 identifies new treatment strategies in hematological cancers. Biochemical Society Transactions, 2017, 45, 457-464.	1.6	28
10	Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma. Blood Advances, 2017, 1, 2257-2268.	2.5	25
11	Intrinsic resistance to PIM kinase inhibition in AML through p38Î±-mediated feedback activation of mTOR signaling. Oncotarget, 2016, 7, 37407-37419.	0.8	16
12	Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors. Molecular Oncology, 2017, 11, 1156-1171.	2.1	15
13	Anagrelide for Gastrointestinal Stromal Tumor. Clinical Cancer Research, 2019, 25, 1676-1687.	3.2	14
14	Evaluating Targeted Therapies in Ovarian Cancer Metabolism: Novel Role for PCSK9 and Second Generation mTOR Inhibitors. Cancers, 2021, 13, 3727.	1.7	13
15	STRN-ALK rearranged pediatric malignant peritoneal mesothelioma â€“ Functional testing of 527 cancer drugs in patient-derived cancer cells. Translational Oncology, 2021, 14, 101027.	1.7	9
16	KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia. Leukemia, 2020, 34, 2780-2784.	3.3	6
17	High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma. Translational Oncology, 2022, 15, 101290.	1.7	4
18	Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles. Blood, 2017, 130, 854-854.	0.6	1

#	Article	IF	Citations
19	AML Specific Targeted Drugs Identified By Drug Sensitivity and Resistance Testing: Comparison of Ex Vivo Patient Cells with in Vitro Cell Lines. Blood, 2014, 124, 2163-2163.	0.6	1
20	Identification Of AML Subtype-Selective Drugs By Functional Ex Vivo Drug Sensitivity and Resistance Testing and Genomic Profiling. Blood, 2013, 122, 482-482.	0.6	0
21	High-Throughput Drug Sensitivity and Resistance Testing (DSRT) Platform Reveals Novel Candidate Drugs For Advanced Phase BCR-ABL1-Positive Leukemia. Blood, 2013, 122, 2719-2719.	0.6	0